Saturday, January 28, 2017 12:28:25 PM
http://www.immunedesign.com/wp-content/uploads/2016/06/LV305-ASCO-poster-2016-final-31May2016-v01.pdf
A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced or Metastatic Cancer Expressing NY-ESO-1
https://clinicaltrials.gov/ct2/show/NCT02122861?term=LV305&rank=1
http://osp.od.nih.gov/sites/default/files/6_1266_ID-LV305_ImmuneDesign_0.pdf
Good luck and GOD bless,
George
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM